Andrew M. Evens, DO, MBA, MSc, is the Deputy Director for Clinical Services at the Rutgers Cancer Institute of New Jersey, Associate Vice Chancellor for Clinical Innovation and Data Analytics at Rutgers Health, and he is Medical Director of the Oncology Service Line and Oncology Lead for the Combined Medical Group for RWJBarnabas Health. He works to further the mission of the State’s only NCI-designated Comprehensive Cancer Center, overseeing the clinical enterprise to deliver innovative, high-quality, and integrated cancer care across 14 acute care hospitals and associated oncology practices throughout New Jersey. He also works closely with Rutgers Health and RWJBarnabas Health system executive leadership teams to advance innovative, efficient, and dynamic clinical decision support systems.

Dr. Evens is an international expert in lymphoid malignancies, with research interests including the study of novel therapeutic agents, biomarkers, predictive modeling, big data, and the implementation of personalized medicine. Nationally, he is a core member of the Hodgkin Lymphoma Working Group for the National Institutes of Health and National Cancer Institute; vice-chair of the Lymphoma Committee for the ECOG-ACRIN NCI research group; co-chair of the Big Ten Cancer Research Consortium lymphoma committee; the editor-in-chief for the British Journal of Haematology; a member of the ASH Research Council Board of Directors; and a re-elected member and the Chair-Elect for the esteemed North American Scientific Advisory Board (SAB) of the Lymphoma Research Foundation (LRF). He is also Professor of Medicine at Robert Wood Johnson Medical School.